Dr. Postow Discusses Side Effects with Combinations in Melanoma

Video

In Partnership With:

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses side effects with combination therapy in melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses side effects with combination therapy in melanoma.

Side effects with combination therapies in melanoma remain a big issue, says Postow. The management of patients’ side effects while on therapy for melanoma is very important, whether it is with combination therapy or monotherapy.

One of the most powerful immunotherapy combinations, ipilimumab (Yervoy) plus nivolumab (Opdiv), does have many side effects despite its efficacy in treating melanoma. Postow says that they are currently trying to tweak that regimen to make it more tolerable for patients, while maintaining its efficacy.

Related Videos
Jeremy M. Pantin, MD, clinical director, Adult Transplant and Cellular Therapy Program, TriStar Centennial Medical Center, bone marrow transplant physician, Sarah Cannon Research Institute
Maria Hafez, MD, assistant professor, breast and sarcoma medical oncologist, director, Clinical Breast Cancer Research, Sidney Kimmel Medical College, Thomas Jefferson University
Zeynep Eroglu, MD
Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor of medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai
Akriti Jain, MD
Raj Singh, MD
Gottfried Konecny, MD
Karim Chamie, MD, associate professor, urology, the University of California, Los Angeles
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Ramez N. Eskander, MD